Requip XL User Fee Date Pushed Back To Second Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA needs additional time to review food effect data from GlaxoSmithKline for the once-daily Parkinson's treatment.
You may also be interested in...
FDA Clears GSK’s Requip XL For Parkinson’s
Once-daily version is designed to battle generic competitors.
FDA Clears GSK’s Requip XL For Parkinson’s
Once-daily version is designed to battle generic competitors.
Generic Requip Cleared For RLS
Teva, Mylan, Roxane and Par will market ropinirole for Restless Legs Syndrome; Parkinson's patent expires this month, too.